Business Wire

CA-AIRSPACE

Share
Airspace Granted Patent for Its Industry-Changing Logistics Management System

Airspace today announced it has been granted a U.S. patent for its optimized logistics management system as of March 2. The patent covers the system, method, and computer programming of the logistical and graphical presentation of the most optimal path for transporting goods from a pickup location to a destination location at lowest transit cost and minimal risk.

Airspace leverages its patented technology and world-class team to provide certainty in the time-critical logistics space through unrivaled speed and shipment transparency . The routing operation is arguably the most important step in the logistical transportation process because the optimal route saves both money and time, while enabling customers to monitor progress along the route provides transparency.

“This technology is a game-changer for the supply chain and logistics industry,” said Ryan Rusnak , co-founder and CTO at Airspace.

Airspace’s technology calculates the best routes in less than a second instead of the typical 30 minutes or more that are standard in the time-critical shipping industry. The router generates a time and space expectation of where each order should be at any given time, which is checked via distributed sensors. Even if an expected flight is canceled, the technology immediately establishes a new plan and tracks it. Airspace provides automated notifications in real time to the customer instead of having to wait for personal contact calls, generating leading indicators rather than lagging ones.

“Our transparency with this process creates trust and confidence for both shippers and receivers,” said Rusnak. “We believe we are setting a new standard for the logistics industry.”

Logistical challenges are difficult because most shipments don’t start at an airport; they start at an arbitrary place such as a lab, warehouse, hospital, and so on. Airspace’s technology takes into consideration ground travel time as well, allowing for traffic to and from nearby airports to the final destination. This technology can provide the difference between life and death, for example, in the case of organs for transplant.

“If you choose a route that doesn’t give the driver enough time, you set the shipment up for failure. Create a route that is too conservative, and you risk losing the last flight that gets the package there when it’s needed,” said Nick Bulcao , co-founder and CEO of Airspace. “This is the extremely difficult optimization challenge that only Airspace can solve today, using our proprietary software and artificial intelligence. We are extremely proud of our inventors and pleased that our technology can make a real difference.”

Airspace, which recently closed its Series C funding round , is positioned to provide the best customer experience for clients while relentlessly analyzing data to address ongoing needs. It continues to grow, focused on making international expansion as seamless as possible by blending operations and R&D for the benefit of the industry.

About Airspace

Airspace, founded in 2016, has grown to be a leading global delivery network for time-critical logistics. Airspace makes shipping faster, safer, and more transparent than ever through its people, service, and technology. From real-time, data-driven notifications to tracking over 16,000 touchpoints, Airspace surfaces more information than any other provider, increasing trust and transparency of the supply chain. To learn more, visit www.airspace.com . Follow Airspace: Twitter , Facebook , Instagram and LinkedIn .

Link:

ClickThru

Social Media:

https://www.facebook.com/AirspaceLogistics/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye